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ABSTRACT
Objectives: Inverse probability of treatment weighting (IPTW) has been
used in observational studies to reduce selection bias. For estimates of the
main effects to be obtained, a pseudo data set is created by weighting each
subject by IPTW and analyzed with conventional regression models. Cur-
rently, variance estimation requires additional work depending on type of
outcomes. Our goal is to demonstrate a statistical approach to directly
obtain appropriate estimates of variance of the main effects in regression
models.
Methods: We carried out theoretical and simulation studies to show that
the variance of the main effects estimated directly from regressions using
IPTW is underestimated and that the type I error rate is higher because of
the inﬂated sample size in the pseudo data. The robust variance estimator
using IPTW often slightly overestimates the variance of the main effects.
We propose to use the stabilized weights to directly estimate both the main
effect and its variance from conventional regression models.
Results: We applied the approach to a study examining the effectiveness of
serum potassium monitoring in reducing hyperkalemia-associated adverse
events among 27,355 diabetic patients newly prescribed with a renin-
angiotensin-aldosterone system inhibitor. The incidence rate ratio (with
monitoring vs. without monitoring) and conﬁdence intervals were 0.46
(0.34, 0.61) using the stabilized weights compared with 0.46 (0.38, 0.55)
using typical IPTW.
Conclusions: Our theoretical, simulation results and real data example
demonstrate that the use of the stabilized weights in the pseudo data
preserves the sample size of the original data, produces appropriate esti-
mation of the variance of main effect, and maintains an appropriate type
I error rate.
Keywords: conﬁdence intervals, incidence rate ratio, inverse probability of
treatment weighting, stabilized weights, type I error rates.
Introduction
Observational studies have been used by medical researchers
seeking to make inference on the effect of treatments on out-
comes. Compared with those in randomized clinical trials, par-
ticipants’ characteristics in an observational study may not be
balanced between treated and untreated groups. Consequently,
the estimate of a treatment effect may be biased without appro-
priate adjustment when receipt of treatment is dependent on
patients’ characteristics (confounders) that also are associated
with outcomes. Propensity scores were introduced by Rosen-
baum and Rubin [1,2] and have been used by many researchers
to obtain the treatments effects in observational studies [3–8]. A
propensity score is the probability of receiving treatment given a
set of known covariates and can be used to balance covariates
between treated and untreated to obtain an unbiased estimate of
treatment effects. Typically, propensity scores in an observational
study can be obtained from ordinary logistic regressions if the
treatment is binary.
The simplest use of propensity scores is that they can be
included as covariates in outcome modeling. One can ﬁrst ﬁt a
propensity score model that includes many potential covariates,
and then the outcome model only has to include the propensity
score and a few covariates that have no association with treat-
ment [3,9]. But this approach can perform poorly if the sample
linear discriminant based on covariates is not a monotone func-
tion of propensity score [1]. There are three additional strategies
that use propensity scores to reduce selection bias: matching,
stratiﬁcation, and inverse probability of treatment weighting
(IPTW). Matching subjects in treated groups with those in
untreated groups with similar propensity scores can balance the
known covariates and reduce selection bias. But it can also result
in signiﬁcant loss of observations of treated subjects, particularly
if the untreated pool is small. Stratiﬁcation places subjects into
several mutually exclusive groups or strata. Based on their pro-
pensity scores, treatment effects are estimated from each stratum
and averaged across strata to estimate the overall treatment effect
[3,10]. The limitation of stratiﬁcation is that one overall treat-
ment effect may not be interpretable when the treatment effects
of strata are very different in scale especially in direction. In
addition, subjects in different strata may not separate into dis-
tinguishable groups that are meaningful to clinicians. The third
propensity score approach is to use IPTW-weighted estimators to
obtain treatment effects adjusting for known confounders
[6,11,12]. This approach can incorporate time-dependent cova-
riates and deal with censored data and produce one overall
estimate of treatment effect.
For continuous outcome variables, there are three unbiased
estimators for treatment effects [10,12] based on the IPTW, which
have shown consistency but with different variance estimators.
Nevertheless, these variance estimators are large-sample based
and may produce large variance estimates and decrease efﬁciency
of the estimators [10]. Estimators and variance estimates are less
developed for discrete outcome variables. Accurate variance esti-
mation of the treatment effect is critical to testing hypotheses.
Underestimation of the variance produces inappropriately narrow
conﬁdence intervals and leads to falsely rejecting the null hypoth-
esis. In addition to the large-sample-based variance estimators,
others have suggested the use of the bootstrap method to obtain
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the variance of treatment effects [13,14], which can be used for
medium or large samples and for different effect measures, for
example, difference for continuous outcomes, incidence rate ratio
for count data, and odds ratio for dichotomous outcomes. Nev-
ertheless, the bootstrap method is not suitable for small data sets
because there are few values to select from and it involves complex
programming [15,16]. A robust variance estimator [13,17,18] has
also been used to obtain standard error of the treatment effect.
This approach adjusts for the lack of independence in replications
of records for a subject in the pseudo data and is available in
common statistical software packages such as the SAS PROC
GENMOD (SAS Institute, Cary, NC). There are also a variety of
weights developed based on sampling designs in survey studies to
accurately compute estimates of population statistics and their
standard errors from a small sample [19].
The aim of this study was to evaluate the use of stabilized
weights (SWs) to obtain directly from conventional regression in
observational studies both the treatment effects and their appro-
priate conﬁdence intervals in the presence of confounders. In
addition, we provide some comparisons of type I error rates
using SWs to the robust variance estimator.
Statistical Methods
Let z be an indicator of binary treatment with 1 for treated and
0 for untreated, X be a row vector of confounders for the
probability of treatment and outcome, p be the propensity score,
and y be the outcome variable. Suppose that there are N subjects
in a data set, with n1 subjects who received the treatment and n0
subjects who did not, N = n0 + n1. The probability of treatment
without considering covariates is p = n1/N, and the probability of
no treatment is 1 - p. The propensity score pi = prob (z = 1|Xi) is
the probability of treatment given the observed covariates Xi.
The propensity score can be estimated with a logistic regression
model π
β
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Nw is always greater than N, the sample size of the original data.
To examine this further, assume that there is only one covariate,
x1, which is dichotomous and associated with the probability of
being treated with a coefﬁcient bx1z. For subjects with x1 = 0, let
m1 be the number of treated subjects and m0 be the number of
untreated subjects, M = m1 + m0, and e0 is the probability
of being treated when x1 = 0. For subjects with x1 = 1, let l1
be the number of treated subjects and l0 be the number of
untreated subjects, and L = l1 + l0, and e1 is the probability of
being treated when x1 = 1. The sample size of the pseudo data
with IPTWs is
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Substituting eˆ0 and eˆ1 into Equation (1),
N M M L L Nw = + + + = 2 (2)
Thus, the sample size doubles in the pseudo data. This is also true
when there are other categorical variables that are associated
with the probability of being treated. Consequently, regression
estimates with IPTWs tend to reject the null hypothesis too
frequently because of inﬂated sample sizes.
An improvement to the IPTW is the use of SWs. SWs have
been proposed in modeling time-varying treatment status in
reducing selection bias in observational studies [20,21]. The
purpose of using SW in these studies is reducing the weights of
either those treated subjects with low propensity scores or those
untreated subjects with high propensity scores. For this article,
we only considered constant treatment status, if zi = 1 then
SW
p
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p
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, where p is the prob-
ability of treatment without considering covariates. We will show
that the use of SW reduces the type I error by preserving the
sample sizes in pseudo data sets. Again, assuming that there is
only one dichotomous predictor for the probability of being
treated, x1, p can be estimated from data as pˆ
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Equation (3) demonstrates that using SWs in observational
studies will result in a pseudo data with sample size that is the
same as that of the original data. Thus, the variance estimate of
treatment effect is appropriate directly from conventional regres-
sion with SWs. This is also true when other categorical variables
that are associated with the probability of being treated exist.
The impact of continuous variables on sample size in the pseudo
data cannot be revealed in closed forms and will be evaluated by
simulations in the next section.
Simulation Studies and Results
The simulations were designed to evaluate the use of SWs to
estimate the effect of treatment and its variance in the presence of
confounders and to obtain appropriate conﬁdence intervals using
conventional regressions analyzing data from observational
studies. Speciﬁcally, we examined the sample sizes in the pseudo
data sets and type I error rates when confounders in the propen-
sity score and outcome models were dichotomous, categorical,
and continuous.
Simulation Algorithm
Probability model for treatment, z. The treatment indicator vari-
able, z, was simulated according to model (4)
π α β α β
α β= =( ) =
+( )
+ +( )prob z X
X
X
z xz
z xz
z xz
1
1
, ,
exp
exp
, (4)
where a is the intercept and is equal to 0.69 and X is a row vector
of dichotomous, categorical, or continuous independent vari-
ables (confounders). We report the results with independent vari-
ables in model (4) being dichotomous, or dichotomous and
continuous variables. Nevertheless, results were similar when
categorical variables were included in model (4).
For simulations with only a dichotomous variable x1, distri-
butions of the dichotomous variable x1 were either 50% = 0 and
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50% = 1 or 66.6% = 0 and 33.3% = 1. For simulations with a
dichotomous variable, x1, and a continuous variables, x2, when
x1 = 0, themean of x2 was either 1 or -1, and the variancewas held
constant at 1; when x1 = 1, the mean of x2 ranged from -4 to 4 by
increments of 1, and the variance was held constant at 4. We also
evaluated different values of the coefﬁcients bx1z, bx2z, bx1y, and bx2y
to reﬂect differing strengths of association with treatment and
outcome. For dichotomous x1, we evaluated positive and negative
values of 0.69, 1.39, and 1.79, which correspond to odds ratios of
2, 3, and 4 when positive. For the continuous variable x2, simu-
lations used values of 0.3, 0.6, and 1.2 for bx2z and bx2y.
We then generated the dichotomous treatment variable zi
based on the treatment probability model (4), i = 1 to 500.
Probability model for the outcome, y. The dichotomous
outcome variable, y, was simulated, based on the following
model:
prob y z
z X
z X
y zy xy
y zy xy
y zy xy
=( ) = + +( )
+ + +( )1 1, , ,
exp
exp
α β β α β β
α β β , (5)
where ay is the intercept and equals to 0.69, bzy is the coefﬁcient
for the association between treatment and outcome and is
assigned zero to assess the type I error rates. X are confounders
and bxy are the corresponding coefﬁcients, and their values are
the same as those of bxz in (4). The dichotomous outcome vari-
able yi was generated based on the outcome probability model
(5), i = 1 to 500.
Analysis of each simulated dataset. For each dataset we ﬁt the
propensity score models, obtained the IPTW and SWs, and then
calculated the sample sizes in the pseudo data and ﬁt outcome
model. 5000 datasets were simulated and analyzed for each
combination of parameters.
Evaluation Measures
Mean sample sizes and standard deviations from 5000 simulated
data sets were estimated. Type I error rates were computed as the
proportion of P-values less than 0.05 under a null hypothesis of
no treatment effect (bzy = 0) based on Wald tests. In addition to
IPTW and SW methods, type I error rates using robust variance
estimator with IPTWs are also reported.
Simulation Results
Sample sizes and type I error rates when there is only a dichoto-
mous confounder x1 and bzy = 0. We ﬁrst evaluated the use of
SWs when there is only a dichotomous confounder, x1 and there
is no treatment effect, bzy = 0. Under a variety of conditions, the
IPTW method clearly doubled the sample sizes in the pseudo data
set and inﬂated the type I error rates (Table 1). SWs preserved the
sample sizes and had type I error rates that were close to 5%
(Table 1). The standard deviations of sample sizes in the pseudo
data sets were small, indicating that the samples sizes of these
5000 pseudo data sets were all about 500, the original simulated
sample size. The level of imbalance of the dichotomous con-
founding covariate between treated and untreated groups had no
impact on the sample sizes of the pseudo data sets and type I
error rates with the SW method. Compared with SWs, the robust
variance estimator method consistently produced lower than 5%
type I error rates because of slightly larger variance estimates.
This is consistent with previous studies [17,18].
Sample sizes and type I error rates when there are a dichotomous
confounder x1 and a continuous confounder x2 and
bzy = 0. Sample sizes with SWs remained similar to the original
simulated sample size with small standard deviations in most of
cases (Table 2). Larger differences emerged when the confound-
ing effect of the continuous variable is strong (bx2z = bx2y = 1.2).
In those simulations, standard deviations became relatively large,
implying greater deviation of some pseudo data set sample sizes
from the original, although the average sample size still remained
about at 500. In addition, type I error rates became as high as
12%. Also, the level of imbalance of the continuous confounding
covariate between treated and untreated groups has no impact on
the sample sizes of the pseudo data sets and type I error rates
with the SW method. Again, Table 2 showed that, on average,
using IPTW doubled sample sizes in the pseudo data, with the
type I error rates reaching as high as 44.0%. For most of the
cases with continuous confounding covariate, the robust vari-
ance estimator method produced lower than 5% type I error
rates because of slightly larger variance estimates.
An Example
In a recent study examining the effectiveness of serum potassium
monitoring in reducing hyperkalemia-associated adverse events
during the ﬁrst year of therapy, 27,355 diabetic patients newly
prescribed with a renin-angiotensin-aldosteronesystem (RAAS)
inhibitor between January 1, 2001 and December 31, 2006 were
retrospectively identiﬁed. Table 3 shows that the patients with
and without serum potassium monitoring in the original cohort
were signiﬁcantly different on many demographic and clinical
characteristics. Nearly three-fourths of this cohort had serum
potassium monitoring during their study follow-up period. This
Table 1 Sample sizes (standard deviations) and type I error rates based on 5000 replications when there is only a dichotomous variable,x1,az = ay = 0.69,
bzy = 0
x1 = 1 (%) bx1z/bx1y
Sample size (STD) Type I error rate (%)
IPTW SW IPTW SW
Robust variance
estimator
33.33 0.69 1000 (1.1) 500 (0.3) 21.2 4.6 4.2
1.39 1000 (3.4) 500 (0.8) 23.1 5.2 4.2
1.79 1000 (5.5) 500 (1.3) 22.8 5.0 3.4
50 0.69 1000 (0.9) 500 (0.2) 22.3 4.7 4.3
1.39 1000 (3.2) 500 (0.6) 25.7 5.2 4.1
1.79 1000 (5.6) 500 (1.0) 26.2 4.6 3.6
33.33 -0.69 1000 (0.2) 500 (0.1) 17.7 4.6 4.2
-1.39 1000 (0.3) 500 (0.2) 16.6 5.2 4.0
-1.79 1000 (0.7) 500 (0.4) 17.5 5.1 3.1
50 -0.69 1000 (0.2) 500 (0.1) 16.3 4.8 4.3
-1.39 1000 (0.2) 500 (0.1) 16.1 5.2 3.8
-1.79 1000 (0.6) 500 (0.2) 17.7 5.4 3.3
IPTW, inverse probability of treatment weighting; STD, standard deviation; SW, stabilized weight.
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study is an example of when matching by propensity scores
would not be optimal because the majority of those with serum
potassium monitoring would be omitted because of a smaller
number of those without serum potassium monitoring.
We ﬁt a logistic regression model to obtain the propensity
scores and included the following variables: use of digoxin, use of
diuretic, use of potassium supplements, study site, sex, drug
groups of RAAS inhibitor, age, kidney transplant, a drug-
dispensing-based chronic disease score based on a modiﬁcation
of the method of Clark et al. [22], potassium monitoring within
6 months before study entry, diagnosis of hyperkalemia within 6
months before study entry, inpatient hospitalization or emer-
gency department visit within 6 months before study entry, the
presence of heart failure, and the presence of chronic kidney
disease. The SW-adjusted results of characteristics comparisons
are presented in Table 3 as well. All covariates except age,
chronic disease score, and the use of potassium supplements
became comparable after SW adjustment between those whose
potassium was monitored and those whose potassium was not
monitored (see Table 3). Although age, chronic disease score, and
the use of potassium supplements remained statistically different
between groups, the magnitudes of difference were markedly
reduced.
The sample size in the pseudo data using the SWs was 27,407
compared with 54,891 using IPTW. The sample size in the
pseudo data using the SWs was only slightly larger than the
original 27,355, and the impact on variance estimate of treat-
ment effect was minimal. The incidence rate ratio and conﬁdence
intervals were 0.46 (0.34, 0.61) using SWs compared with 0.46
(0.38, 0.55) using typical IPTW. While adjusting for age, the use
of potassium supplements, and chronic disease score using SWs,
the incidence rate ratio was 0.49 (0.37, 0.66), which was very
close to the results without the adjustment of these covariates in
outcome model, indicating that the balance of age, the use of
potassium supplements, and chronic disease score between the
two groups with SWs was sufﬁcient. Comparison of these two
weights from this example showed that IPTWs have larger stan-
dard deviations and wider ranges than SWs (Table 4).
Table 2 Sample sizes (standard deviations) and type I error rates based on 5000 replications when there are a dichotomous and a continuous variable,
az = ay = bx1z = bx1y = 0.69, variance(x2) = 1 for x1 = 0 and equal to 4 for x1 = 1
x1 = 1 (%) bx2z/bx2y
Means of x2 Sample size (STD) Type I error rate (%)
x1 = 0 x1 = 1 IPTW SW IPTW SW
Robust variance
estimator
50 0.3 1 1 999 (9.7) 500 (2.0) 25.9 5.1 4.6
0.6 1 1 999 (35.9) 500 (6.7) 28.4 6.3 4.0
1.2 1 1 995 (196.7) 499 (36.7) 35.5 12.0 3.4
0.6 1 2 999 (35.1) 500 (5.1) 32.1 5.1 4.0
0.6 1 3 998 (38.4) 500 (4.4) 36.5 5.0 5.6
0.6 1 4 999 (102.3) 500 (4.6) 41.5 6.0 5.8
33.33 0.3 1 1 999 (8.8) 500 (1.9) 24.0 5.0 4.3
0.6 1 1 999 (31.1) 500 (6.1) 28.5 6.2 4.5
1.2 1 1 996 (152.0) 499 (29.0) 32.8 9.0 3.0
0.6 1 2 1000 (31.1) 500 (4.4) 32.9 5.0 4.4
0.6 1 3 999 (35.7) 500 (3.6) 39.0 4.5 6.2
0.6 1 4 1000 (49.3) 500 (3.8) 43.9 4.5 7.7
0.6 -1 -1 999 (13.6) 500 (5.9) 17.2 5.6 3.3
0.6 -1 -2 999 (12.9) 500 (6.8) 17.8 6.0 2.8
0.6 -1 -3 999 (13.2) 500 (8.0) 20.4 6.8 2.2
0.6 -1 -4 999 (16.5) 500 (9.0) 22.0 6.2 1.4
IPTW, inverse probability of treatment weighting; STD, standard deviation; SW, stabilized weight.
Table 3 Characteristics of patients in the original study cohort and in the pseudo cohort with stabilized weights
Characteristic
Original cohort (n = 27,355) Pseudo cohort (n = 27,407)
Monitored Not monitored P-values Monitored Not monitored P-values
Mean age in years (STD) 60.4 (13.0) 55.5 (13.2) <0.001 59.0 (13.1) 59.3 (13.8) 0.054
Male sex (%) 50.8 53.4 <0.001 51.4 50.7 0.30
Drug groups (%) <0.001 0.98
ACEi 91.9 93.1 92.5 92.3
ARB 5.70 5.5 5.4 5.6
Spironolactone 1.90 1.2 1.6 1.6
Combinations 0.50 0.2 0.5 0.5
Kidney transplant during or before study entry (%) 0.30 <0.1 <0.001 0.2 0.2 0.39
Prior potassium monitoring (%) 0.90 0.93 0.67 0.9 0.9 0.89
Prior hyperkalemia diagnosis (%) 0.57 0.38 0.05 0.5 0.5 0.79
Hospitalization or emergency department visit(s) within 6 months
before study entry (%)
23.50 19.1 <0.001 22.6 22.2 0.39
Heart failure diagnosis (%) 8.9 3.5 <0.001 7.4 7.6 0.66
Chronic kidney disease stage 3 or 4 (%) 10.0 3.0 <0.001 8.0 8.4 0.28
Median chronic disease score (5th, 95th percentile) 6 (3.11) 6 (3.9) <0.001 6 (3.10) 6 (3.11) 0.03
Digoxin therapy (%) 4.4 1.6 <0.001 3.6 3.8 0.40
Diuretic therapy (%) 37.1 19.9 <0.001 32.2 32.8 0.27
Potassium supplement therapy (%) 13.9 4.7 <0.001 11.3 12.3 0.02
ARB, angiotensin receptor blockers; STD, standard deviation.
276 Xu et al.
Discussion
In this article, we demonstrate several advantages of SWs over
IPTWs in analyzing data obtained from observational studies.
First, using SWs can reduce the weights of either those treated
subjects with low propensity scores or those untreated subjects
with high propensity scores in the pseudo data sets. Our serum
potassium monitoring example showed that IPTWs have larger
standard deviation and wider range than SWs (Table 4). Thus,
results using SWs are robust even with few observations with
extreme IPTWs. Second, unlike variance estimators, no addi-
tional steps are needed when SWs are used because the SW
approach provides appropriate variance estimates and conﬁ-
dence intervals of treatment effect from conventional regression
models for ﬁtting the outcome variables. Third, computer pro-
gramming is simple for one to use SWs to obtain the effect of
treatment effects and conﬁdence intervals as compared with the
bootstrap approach. One only needs to calculate the weights
differently. Fourth, in our simulation studies and example,
outcome variables are dichotomous. Unlike those developed esti-
mators, the SW approach is applicable to outcome variables (e.g.,
dichotomous, continuous, and count data) that have a ﬁnite
distribution. Our simulation results also show that SW is a
reasonable alternative to the robust variance estimator and has
the advantage of reducing inﬂuential weights.
The limitation of the SW approach is the uncertainty of the
inﬂuence of continuous confounders when their association with
the probability of being treated and outcome is very strong. As
shown in simulation studies, the sample size in some of the
pseudo data sets can be different from the original data set when
the confounding effect is strong. Nevertheless, it is uncommon
because our simulation results showed that the mean sample size
approximated the original sample size. It is recommended that
one always examine the difference between sample sizes in the
original cohort and the pseudo cohort. When there is evidence
that the sample size of the pseudo data is different from that of
the original data set, one can use the robust variance estimator
with IPTWs although this latter method can produce slightly
larger standard errors.
Conclusion
Our theoretical, simulation results and the real data example
demonstrate that the use of the SWs in the pseudo data preserves
the sample size close to the original data. In addition, we con-
clude that use of SWs produces the appropriate estimation of the
variance of the main effect and maintains an appropriate type I
error rate. SWs may be a useful tool to balance confounders
between groups in observational studies.
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